Correlation between Microvascular Density and Matrix Metalloproteinase 11 Expression in Prostate Cancer Tissues: a Preliminary Study in Thailand

  • Kanharat, Nongnuch (College of Medicine and Public Health, Ubon Ratchathani University) ;
  • Tuamsuk, Panya (Department of Anatomy, Faculty of Medicine, Khon Kaen University)
  • Published : 2015.10.06


Background: Prostate cancer is a major concern of public health. Microvascular density (MVD) is one of the prognostic markers for various solid cancers. Matrix metalloproteinase 11 (MMP11) plays an important role in angiogenesis and changes in its expression level are known to be associated with tumor progression and clinical outcome. Aim: To investigate the relationship between MVD and MMP11 expression in prostatic adenocarcinoma tissues. Materials and Methods: The expression levels of MMP11 and MVD were analyzed immunohistochemically for 50 specimens of prostatic adenocarcinoma. Results: MMP11 was mainly expressed in stromal cells but rarely seen in epithelial cells. Mean MVD was $36/mm^2$, and it was correlated significantly only with bone metastases. MVD was also significantly correlated with MMP11 expression (r=0.29, p=0.044). Conclusions: MMP11 may alter the stromal microenvironment of prostate cancer to stimulate tumor angiogenesis.


Matrix metalloproteinase 11;prostatic adenocarcinoma;Microvascular Density angiogenesis


Supported by : Khon Kaen University


  1. Basset P, Bellocq JP, Wolf C, et al (1990). A novel Metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature, 348, 699-704.
  2. Basset P, Wolf C, Chambon P (1993). Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat, 24, 185-93.
  3. Bono AV, Celato N, Cova V, et al (2002). Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis, 5, 123-7.
  4. Choy M, Rafii S (2001). Role of angiogenesis in the progression and treatment of prostate cancer. Cancer Invest, 19, 181-91.
  5. Concato J, Jain D, Uchio E, et al (2009). Molecular markers and death from prostate cancer. Ann Intern Med, 150, 595-603.
  6. Condon MS (2005). The role of the stromal microenvironment in prostate cancer. Sem Cancer Biol, 15, 132-7.
  7. Deryugina EI, Quigley JP (2015). Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasissustaining neovasculature. Matrix Biol, (in press).
  8. Erbersdobler A, Isbarn H, Dix K (2010). Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol, 28, 687-92.
  9. Escaff S, Fernandez JM, Gonzalez LO, et al (2010). Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br J Cancer, 102, 922-9.
  10. Fidler IJ, Ellis LM, (1994). The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79, 185-8.
  11. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6.
  12. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82, 4-6.
  13. Folkman J (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol, 3, 65-71.
  14. Folkman J, Watson K, Ingber D, et al (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, 58-61.
  15. Gimbrone MA Jr, Leapman SB, Cotran RS, et al (1972). Tumor dormancy in vivo by prevention of neovascularization. J Exp Med, 136, 261-76.
  16. Globocan (2012). Prostate cancer: estimated incidence, mortality and prevalence worldwide in 2012 [Online]. Available:
  17. Iakovlev VV, Gabril M, Dubinski W, et al (2012). Microvascular density as an independent predictor of clinical outcome in renal cell carcinoma: an automated image analysis study. Laboratory Investigation, 92, 46-56.
  18. Kaygusuz G, Tulunay O, Baltaci S, et al (2007). Microvessel density and regulators of angiogenesis in malignant and nonmalignant prostate tissue. Int Urol Nephrol, 39, 841-50.
  19. Kessenbrock K, Plaks V, Werb (2010). Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. Cell, 141, 52-67.
  20. Khuhaprema T, Srivatanakul P, Attasara P, et al (2013). Cancer in Thailand Volume VII 2007-2009. National cancer institute, 7, 12.
  21. Lin CW, Yang SF, Chuang CY, et al (2014). Association of matrix metalloproteinase-11 polymorphisms with susceptibility and clinicopathologic characteristics for oral squamous cell carcinoma. Head Neck, DOI: 10.1002/hed.23771.
  22. Manes S, Mira E, Barbacid MD, et al (1997). Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem, 272, 25706-12.
  23. Min KW, Kim DH, Do SI, et al (2013). Diagnostic and prognostic relevance of MMP-11 expression in the stromal fibroblastlike cells adjacent to invasive ductal carcinoma of the breast. Ann Surg Oncol, 20, 433-42.
  24. Montironi R, Diamanti L, Thompson D, et al (1996). Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol, 30, 191-200.
  25. Murphy G, Segain JP, O'Shea M, et al (1993). The 28-kDa N-terminal domain of mouse stromelysin-3- has the general properties of a weak metalloproteinase. J Biol Chem, 268, 15435-41.
  26. Nagase H, Woesser JF Jr (1999). Matrix metalloproteinases. J Bio Chem, 274, 21491-4.
  27. Nicholson B, Theodorescu D (2004). Angiogenesis and prostate cancer tumor growth. J Cellular Biochemistry, 91, 125-50.
  28. Nonsrijun N, Mitchai J, Brown K, et al (2013). Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma associated with poor survival outcome. Asian Pac J Cancer Prev, 14, 3331-5.
  29. Pei D, Majmudar G, Weiss SJ, (1994). Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem, 269, 25849-55.
  30. Roscilli G, Cappelletti M, Vitis CD, et al (2014). Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. J Translational Med, 12, 54.
  31. Rundhaug JE (2005). Matrix metalloproteinases, angiogenesis, and cancer. J Cell Mol Med, 9, 267-85.
  32. Sinha AA, Quast BJ, Reddy PK, et al (2004). Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer. Experimental and Molecular Pathology, 77, 153-9.
  33. Taille Adl, Katz AE, Bagiella E, et al (2000). Microvessel density as a predictor of PSA recurrence after radical prostatectomy a comparison of CD34 and CD31. Am J Clin Pathol, 113, 555-62.
  34. Tang Y, Nakada MT, Kesavan P, et al (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res, 65, 3193-9.
  35. Tuamsuk P, Nonsrijun N, Pachirat K, et al (2011). Prostate cancer in Srinagarind Hospital. Srinagarind Med J, 26, 373-6.
  36. van Moorselaar RJ, Voest EE (2002). Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Molecular and Cellular Endocrinology, 197, 239-50.
  37. Weidner N, Carroll PR, Flax J, et al (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol, 143, 401-9,
  38. Yodavudh S, Tangjitgamol S, Puangsa-art S (2008). Prognostic significance of microvessel density and mast cell density for the survival of Thai patients with primary colorectal cancer. J Med Assoc Thai, 91, 723-32.
  39. Zhao ZS, Chu YQ, Ye ZY, et al (2010). Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol, 41, 686-96.

Cited by

  1. Insights into the distinct roles of MMP-11 in tumor biology and future therapeutics (Review) vol.48, pp.5, 2016,